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a b s t r a c tHeavy menstrual bleeding (HMB) is a common symptom in patients who present to the obstetrician-gynecologist or adolescent medicine
specialist and might result from an underlying inherited bleeding disorder. Whereas relatively common bleeding disorders such as von
Willebrand disease are often included in standard laboratory assessments, rarer platelet function disorders can be challenging to diagnose.
Additionally, HMB can be a particularly difﬁcult symptom to manage in adolescents with platelet function disorders, and it is associated
with decreased quality of life. We review the diagnostic and management issues of patients with platelet function disorders through the
presentation of 2 patient case reports, with a focus on a diagnosis of Glanzmann thrombasthenia, an inherited qualitative disorder that
affects platelet function. Whereas the ﬁrst patient presented to the emergency department before the diagnosis of a bleeding disorder and
required a hematologic referral and extensive laboratory assessments, the second patient had been diagnosed with Glanzmann throm-
basthenia as a child but experienced severe management challenges at the onset of menarche. In both patients, collaboration between the
obstetrician-gynecologist or adolescent medicine specialist and the hematologist was critical for achieving acute management of the
bleeding symptoms and for ensuring optimal long-term disease management. Together, these cases highlight the importance of properly
identifying females with HMB who might have an undiagnosed bleeding disorder and of consulting with a hematologist to determine an
appropriate management plan throughout all life stages.
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Heavy menstrual bleeding (HMB) is a symptom often
presented to the obstetrician-gynecologist or adolescent
medicine specialist, and it is estimated to affect approxi-
mately 8%-10% of women of reproductive age.1 This type of
bleeding can severely affect quality of life and is associated
with pain and limited social, academic, and professional
activities and achievements.2e4 In most cases, patients
exhibit HMB as only an isolated bleeding symptom that can
be easily managed with hormonal therapy, however, in up
to 20% of women with HMB, this symptom might be a sign
of an underlying coagulation disorder.5 Although severe
coagulation disorders are often diagnosed before the age of
menarche, causes of HMB are only identiﬁed in an esti-
mated 50% of cases, and therefore, many women with HMB
might have an undiagnosed bleeding disorder with HMB
being the predominant symptom.6
For girls with bleeding disorders in which HMB presents
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medical providers of the indications that laboratory testing
or a hematologic referral might be necessary is critical to
obtaining an accurate diagnosis. An initial laboratory eval-
uation is recommended by the American College of Obste-
tricians and Gynecologists for all patients who present with
acute abnormal uterine bleeding, and further testing might
be necessary for females with an initial indication of he-
mostatic dysfunction.5 The coagulation disorders most
commonly associated with HMB and other types of muco-
cutaneous bleeding include von Willebrand disease (VWD)
and platelet function disorders.7e9 Whereas VWD is rela-
tively common and often included in standard laboratory
assessments,5 platelet function disorders can be challenging
to diagnose, because bleeding patterns appear similar across
a wide variety of platelet disorders, and defects in platelet
function (as opposed to platelet quantity) are often not
revealed through initial screening laboratory assessments.10
Among the inherited platelet function disorders, Glanz-
mann thrombasthenia (GT) is the most common.11 This
autosomal recessive coagulation disorder is characterized by
quantitative or qualitative abnormalities of the platelet
membrane glycoproteins IIb or IIIa (GPIIb/IIIa) that mediate
binding to ﬁbrinogen, resulting in reduced platelet aggre-
gation or clumping. Similar to patients with other platelet
function disorders, patients with GT typically present with
mucocutaneous bleeding episodes, and HMB can be alished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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tion disorders in adolescents with HMB is important for
identifying those with undiagnosed bleeding conditions
such as GT, and an accurate diagnosis might prevent poten-
tially severe complications such as unnecessary surgical in-
terventions. A familiarity of adolescent medicine specialists,
gynecologists, and other medical providers with the clinical
presentation of GTand other rare platelet function disorders
is therefore important for understanding the clinical in-
dications for which a hematology workup or consultation
might beuseful and for ensuring the appropriate therapeutic
management of patients with an existing diagnosis. Herein
wepresent 2 illustrative cases of female adolescents with GT
whoexperiencedHMBanddiscuss the challenges associated
with diagnosis and management of this and other rare
platelet function disorders. These examplesmight serve as a
useful guide for understanding the considerations most
relevant to health care professionals when encountering
patients with severe or unexplained HMB.Case Reports
Case Report 1
An 11-year-old girl presented to the emergency depart-
ment 9 days after the start of her ﬁrst menstrual period. The
patient had been experiencing severe vaginal bleeding,
which she reported was most severe on day 4. She had used
a total of 48 menstrual pads, which she had been changing
almost every 15 minutes, and she complained of fatigue,
dizziness, and lightheadedness. She complained of having a
headache for 2 days and had experienced a syncopal
episode 3 days earlier. She was not currently receiving any
hormonal medications and denied sexual activity.
The patient's medical history was signiﬁcant for recur-
rent nose bleeds since 2 years of age, which occurred 2 to 3
times per month and typically lasted 10 to 15 minutes.
These episodes of epistaxis were controllable at home and
never required urgent medical intervention. She also had a
history of easy bruising, although she had no evidence of
joint bleeds. She had never undergone any surgical pro-
cedures. She had not had any laboratory testing for anemia
in the past few years, and her family history was notable for
some reports of relatives with “heavy periods.”
Upon initial evaluation in the emergency department, the
patient was alert, oriented, and cooperative with the ex-
amination, although she appeared tired andpale.Herweight
was 38.2 kg, and her vital signs showed a heart rate of 120
beats per minute and a blood pressure of 90/60 mmHg. Her
physical examination revealed normal heart and lung func-
tion and no hepatosplenomegaly. Her neurologic examina-
tion was nonfocal. Nonpalpable ecchymoses of varying ages
were noted on her back and extremities. Although a specu-
lum examination was not performed, an external genito-
urinary examination revealed no evidence of vulvar
hematoma or other trauma.
The patient underwent an initial laboratory workup
including a blood type and antibody screen, complete blood
count (CBC), analysis of prothrombin time (PT) and partial
thromboplastin time (PTT), and platelet function analyzer100 (PFA-100) assessment to screen for bleeding disorders.
These initial analyses revealed moderate anemia (hemo-
globin 7.3 g/dL), a normal platelet count (200,000/mL), and
normal PT (11 seconds) and PTT (32 seconds). PFA-100 re-
sults were abnormal with collagen-epinephrine and
collagen-adenosine diphosphate (ADP), although these re-
sults were interpreted with caution because of the presence
of anemia. A urine pregnancy test was negative. The patient
received a transfusion of 2 units of packed red blood cells
(PRBCs) and was admitted to the adolescent medicine ser-
vice for further management.
The adolescent medicine physician obtained a hematol-
ogy consult for additional laboratory evaluations, including
a repeat CBC, examination of peripheral blood smear, von
Willebrand screen, and platelet aggregation studies. Ana-
lyses showed an improved hemoglobin level of 9.2 g/dL and
normal morphology of platelets and red and white blood
cell lines. The patient was shown to have normal levels of
von Willebrand antigen, ristocetin cofactor, and factor VIII.
Platelet aggregation studies revealed abnormal platelet
aggregation with a lack of aggregation with all agonists
(ADP, epinephrine, and collagen) except for ristocetin,
which was conﬁrmed with retesting, indicating a diagnosis
of GT. The patient was treated with an antiﬁbrinolytic agent
and received platelet transfusion. No potential estrogen
contraindications had been identiﬁed, such as a personal
history of thrombosis or stroke, thrombogenic mutations,
migraine with aura, or severe cirrhosis, and a combined oral
contraceptive (COC) taper was started. Results of follow-up
platelet immunophenotyping using ﬂow cytometry were
consistent with a diagnosis of GT; the patient exhibited
greatly reduced expression of CD41 and CD61, markers of
GPIIb and GPIIIa, respectively, but normal expression of
CD42b, a marker for GPIb.
Case Report 2
A 13-year-old girl with a conﬁrmed diagnosis of GT
presented to the emergency department with severe
menstrual bleeding 14 days after the start of her ﬁrst
menstrual period. She had been experiencing dizziness and
syncope for several hours. The patient's history included a
diagnosis of GT at 14 months of age after symptoms of
recurrent epistaxis and severe bruising. Previous hospitali-
zations included a case of severe epistaxis at 4 years of age
and prolonged bleeding associated with a dental extraction
at 12 years of age, both of which required platelet and PRBC
transfusions. Response to platelet transfusion during the
second admission was noted to be diminished compared
with the previous episode. She denied any history of sexual
activity or vaginal penetration and had never been pre-
scribed any hormonal medications.
Initial laboratory evaluation in the emergency depart-
ment revealed severe anemia (hemoglobin level of 6.1 g/dL)
and a negative urine pregnancy test. The patient's hema-
tologist was contacted, and upon her recommendation the
patient was treated acutely with recombinant activated
factor VII (rFVIIa; NovoSeven RT; Novo Nordisk, Bagsvaerd,
Denmark) and aminocaproic acid to control the bleeding
and a 2-unit PRBC transfusion to address the acute anemia.
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hemostatic response experienced during the bleeding
episode that occurred 1 year earlier. After consultation be-
tween the hematologist and adolescent medicine specialist,
COCs were started and the patient was discharged after
2 days in stable condition.
During the patient's second menstrual period, she again
experienced severe menstrual bleeding requiring hospital
admission and treatment with rFVIIa, aminocaproic acid,
and PRBC transfusions. Her adolescent medicine specialist
prescribed a higher-dose COCs, which effectively stopped
her menstrual bleeding.
Discussion
HMB has been formally deﬁned as bleeding lasting more
than 7 days and/or a blood loss of more than 80 mL per
menstrual cycle.13 Other clinical clues to abnormally heavy
bleeding include changing a product (eg, pad or tampon)
after only 1-2 hours, requiring double protection (pad and
tampon), needing to change a product at night, and the
passage of large blood clots. Although most cases of HMB
occur in the absence of other bleeding symptoms and can
easily be controlled with standard hormonal therapies,
cases of HMB can be challenging for physicians to manage
and are often associated with disorders of hemostatic
function.
Platelet function disorders typically present with symp-
toms of severe mucocutaneous bleeding and are often
diagnosed in childhood after manifestations such as
epistaxis or oral/gum bleeding. In these situations, the risk
for HMB is understood and can be planned for in affected
females; however, the management of HMB can be highly
challenging in patients with known disease, as illustrated
by the second case presented in this report. For some pa-
tients, HMBmight be the ﬁrst clinically signiﬁcant symptom
that prompts evaluation by medical professionals, and
therefore, recognizing any signs of unusual bleeding and
ensuring the performance of appropriate hemostatic as-
sessments are critical for obtaining an accurate diagnosis.
GT and other platelet function disorders are less common
than other coagulation disorders, such as VWD and coag-
ulation factor deﬁciencies, however, bleeding associated
with GT and other platelet function disorders can be severe,
and HMB is often a particularly challenging symptom.14,15
Initial Assessment and Hematologic Referral
Obtaining an accurate sexual history is important for
evaluating potential causes of HMB. Sexually active females
should be screened for chlamydia and gonorrhea using
nucleic acid ampliﬁcation testing of urine or vaginal or
cervical swabs as part of a thorough evaluation to exclude
infectious cervicitis and pelvic inﬂammatory disease as
causes of excessive vaginal bleeding.16,17 Additionally, in
some cases, a speculum examination may be performed to
conﬁrm that bleeding is not caused by a vaginal laceration
or retained foreign body. Importantly, sexual activity and
trauma should be considered even in patients with
extremely HMB or a known bleeding disorder, because ableeding disorder does not exclude the potential for exac-
erbated bleeding caused by sexual or other trauma. Pelvic
ultrasound examinations are commonly used in gyneco-
logic evaluation and might identify causes of HMB such as
ﬁbroids and endometrial polyps, however, these ﬁndings
are rare in the adolescent population, and therefore, the
value of a pelvic ultrasound in elucidating an etiology for
HMB in young women might be limited. However, pelvic
imaging should be considered for abnormal uterine
bleeding accompanied by abdominal or pelvic pain, pelvic
mass, or increased abdominal girth.18,19
Because the adolescent medicine specialist or gynecol-
ogist often performs the ﬁrst evaluation of a patient's HMB,
awareness among these physicians of potential underlying
coagulation disorders, as well as the appropriate steps to-
ward obtaining an accurate diagnosis, are important for
long-term disease management. A comprehensive patient
history might provide indications that further hemostatic
assessment is warranted, including a history of easy
bruising, excessive bleeding (particularly gingival and
epistaxis), and bleeding after tooth extraction or surgery.
The occurrence of iron deﬁciency anemia or a previous
emergency department visit or inpatient admission for
HMB also indicates that a hematology consult might be
necessary. Examining a patient's family history might be
useful in determining which patients should receive coag-
ulation assessments and referrals to a hematologist. For
patients with known bleeding disorders, comanagement
with a hematologist is important for ensuring optimal care.
Coagulation Laboratory Assessments
Preliminary blood work for patients with a suspected
coagulation disorder typically includes a CBC, ﬁbrinogen
level assessment, and screening coagulation assays
including PT and PTT; however, these assessments provide
limited information regarding potential platelet dysfunc-
tion. Platelet count, size, and morphology are typically
normal in patients with GT, although anemia (low hemo-
globin levels) might be observed as a result of blood loss.
Fibrinogen, PT, and PTT assessments are also usually in the
normal range in patients with GT.
After preliminary blood work, patients with a suspected
platelet function disorder should undergo additional
platelet function studies, which might require consultation
with or referral to a hematologist. Closure time analysis
provides a rapid indication of platelet function and is per-
formed with the PFA-100 system. PFA-100 is highly sensi-
tive, however, the system lacks speciﬁcity and cannot
differentiate between speciﬁc platelet function disorders20;
furthermore, PFA-100 results can be falsely abnormal in the
presence of anemia, which often occurs in cases of severe
recurrent HMB. Platelet aggregometry is the gold standard
for the diagnosis of platelet function disorders; this
assessment can distinguish GT from other platelet function
disorders because of an absent or severely decreased ag-
gregation response toward all agonists (ADP, epinephrine,
collagen, thrombin, and arachidonic acid) except for risto-
cetin. An important consideration in performing closure
time analysis and platelet aggregation testing is use of
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oxygenase [COX]-1 inhibitors, b-lactam antibiotics, and se-
lective serotonin reuptake inhibitors), which can interfere
with test results. Flow cytometry using monoclonal anti-
bodies directed against membrane GPIIb and GPIIIa (CD41
and CD61, respectively) can be used to conﬁrm the diag-
nosis of GT, because patients with GT exhibit decreased or
absent binding of either of these antibodies.11 Importantly,
ﬂow cytometry is also a useful technique for determining
the carrier status of family members.21
Because many platelet function disorders present with a
similar mucocutaneous bleeding proﬁle, a careful differen-
tial diagnosis among patients with a suspected platelet
function disorder is important for obtaining an accurate
diagnosis (Table 1). Important diagnoses to evaluate include
coagulation factor deﬁciencies and VWD, which can be
excluded with normal PT/PTT and von Willebrand test re-
sults. Thrombocytopenia can be excluded with a normal
platelet count, and platelet signal transduction disorders
and platelet agonist receptor deﬁciencies can be excluded
through aggregation studies.
Management of Platelet Function Disorders
Acute management of bleeding episodes involves
achieving hemostasis and also addressing acute or chronic
anemia. Hemostatic management is generally guided by the
hematologist, and in patients with GT or other platelet
function disorders, treatment commonly involves platelet
transfusions. Important concerns in treating patients with
platelets are the potential development of antibodies to the
normal GPIIb/IIIa present on the transfused platelets or to
human lymphocyte antigen and reduced responsiveness to
platelets (refractoriness). For these reasons, and in the
absence of signiﬁcant data to predict when and if antibodies
or refractoriness will occur, platelets may be used sparingly
in children with frequent bleeding and reserved for severe
episodes or surgery. Antiﬁbrinolytics act by inhibiting clotTable 1
Differential Diagnosis of Inherited Bleeding Disorders in Patients with HMB and Key Lab
Diagnosis PT aPTT Platelet Count
Platelet function disorders
Platelet agonist receptor deﬁciencies Normal Normal Normal
Bernard-Soulier syndrome Normal Normal Decreased
Glanzmann thrombasthenia Normal Normal Normal
Platelet storage pool deﬁciencies Normal Normal Normal or
decreased
Clotting factor deﬁciencies
Intrinsic pathway factor deﬁciency
(FVIII, FIX, FXI)
Normal Prolonged Normal
Extrinsic pathway factor deﬁciency (FVII) Prolonged Normal Normal
Common pathway factor deﬁciency
(ﬁbrinogen, FII, FV, FX)
Prolonged Prolonged Normal





Congenital thrombocytopenia Normal Normal Decreased
ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; FII, factor II; F
HMB, heavy menstrual bleeding; PFA-100, platelet function analyzer 100; PT, prothrombreakdown (ﬁbrinolysis) and are often a convenient treat-
ment option because of an oral route of administration and
potential for use in the home setting. rFVIIa has been
studied in the acute setting in patients with and without
refractoriness and has been approved in the United States
and Canada for the treatment of patients with refractoriness
to platelets with or without antiplatelet antibodies22,23 (and
in Canada for those without immediate access to plate-
lets),23 and has been approved in Europe for patients with
refractoriness and antiplatelet antibodies.24
Continued management of HMB and other bleeding
symptoms inpatientswith platelet function disorders should
be coordinated between the hematologist, adolescent med-
icine specialist or gynecologist, and primary care physician.
COCs aremost often the ﬁrst-line therapy for ongoing control
of HMB, regardless of the presence of platelet function dis-
orders. Patients who fail to respond to COCs, and those who
are severely anemic or who are unable to tolerate oral
medication, may be started on intravenous estrogen to con-
trol bleeding, with a progestin component added later to
stabilize the endometrium.25 Progestin-secreting intrauter-
ine devices might be used to control HMB in patients with
platelet functiondisordersby suppressingmenses altogether.
Levonorgestrel intrauterine devices (ie, Mirena; Bayer
HealthCare Pharmaceuticals Inc, Whippany, NJ) have also
been shown to reduce the severity ofmenstrual bleeding and
improve quality of life in patients with HMB related to
bleeding disorders.26,27 Other progestin-only medications
such as norethindrone acetate and medroxyprogesterone
acetate may be prescribed depending on the clinical sce-
nario.28 When considering in-ofﬁce placement of intrauter-
ine devices or other invasive hormonal measures in patients
with platelet function disorders, consultation with a hema-
tologist may be critical for managing potential bleeding that
might arise during the procedure; in some cases physicians
might opt to perform the procedure in an in-patient setting.
It is imperative that fertility preservation inform the




Normal or prolonged Platelet aggregation absent to ADP or arachidonic acid
Prolonged Giant platelets; platelet aggregation normal with all
agonists but decreased to ristocetin
Prolonged Platelet aggregation absent or decreased with all
agonists except to ristocetin
Normal or prolonged Platelet aggregation absent to epinephrine or abnormal
second wave to intermediate-dose ADP
Normal Measured with speciﬁc factor assays
Normal Measured with speciﬁc factor assays
Normal Measured with speciﬁc factor assays
Normal or prolonged von Willebrand panel abnormal (von Willebrand
factor activity and antigen; FVIII activity and
multimer analysis)
Normal or prolonged ‒
V, factor V; FVII, factor VII; FVIII, factor VIII; FIX, factor IX; FX, factor X; FXI, factor XI;
bin time
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management failed to control their HMB. Balloon tampo-
nade is a fertility-preserving option that has been success-
fully used in adolescents.29,30 Procedures such as uterine
artery embolization, endometrial ablation, and hysterec-
tomy are reserved for patients for whom childbearing is
complete31; exceptions to this rule are likely to be consid-
ered only in life-threatening cases.32
Cultural and Psychosocial Issues and Challenges
TheeffectofHMBonpsychosocialwell-beingandqualityof
life is an important issue for youngpatients. HMBoften causes
substantialpainandmanagementburdens, andhighnumbers
of patients report missing work, school, and social activities
becauseof theirHMB.2e4Otherqualityof life issues associated
with GT include limited participation in sports and other
physical activities, falling behind in school becauseof frequent
absences, concerns of parental abuse because of frequent and
often severe bruising, and teasing or marginalization.33 Difﬁ-
culties associatedwith leaving class to use a restroomcanalso
be an issue for teenagers with HMB, and providers might
therefore offer written notiﬁcation to school personnel
emphasizing the medical necessity of adequate bathroom
access in this patient population. Furthermore, busy school/
activity schedules can make adherence to COCs difﬁcult, and
missed doses can cause severe breakthrough bleeding that
might occur quickly. Cultural or religious objections toward
the use of hormonal therapy or blood transfusions, particu-
larly because of an implication of sexual activity associated
with the use of oral contraceptives in certain cultures, might
also create barriers to effective treatment.
Conclusions
Patients with rare bleeding disorders can present with
severe menstrual bleeding, and a thorough hemostatic
assessment of patients with abnormal uterine bleeding is
critical for obtaining an accurate diagnosis. A review of
these 2 patient case reports shows that HMB in patients
with rare platelet disorders such as GT can be challenging
for healthcare professionals to manage and can severely
affect patients' quality of life.
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